Evidence map›Paper›PMID 35084696›Full record

ReviewPaediatric drugs2022

Drug Treatment of Heart Failure in Children: Gaps and Opportunities.

Molly Weisert, Jennifer A Su, Jondavid Menteer, Robert E Shaddy, Paul F Kantor

Abstract readReview
PubMed Publisher
In one paragraph

Review in Paediatric drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Molly WeisertDepartment of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jennifer A SuDepartment of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jondavid MenteerDepartment of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Robert E ShaddyDepartment of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Paul F KantorDepartment of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. pakantor@chla.usc.edu.ORCID http://orcid.org/0000-0003-3071-9289
University of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medical therapy for pediatric heart failure is based on a detailed mechanistic understanding of the underlying causes, which are diverse and unlike those encountered in most adult patients. Diuresis and improved perfusion are the immediate goals of care in the child with acute decompensated heart failure. Conversion to maintenance oral therapy for heart failure is based on the results of landmark studies in adults, as well as recent pediatric clinical trials and heart failure guidelines. There will continue to be an important role for newer drugs, some of which are in active trials in adults, and some of which are already approved for use in children. The need to plan for clinical trials in children during drug development for heart failure is emphasized.

Indexed as

Heart FailureAdultChildHumans

Identifiers

PMID35084696
OpenAlexW4210554946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.